{"id":"W4399451380","doi":"10.1200/jco.2024.42.17_suppl.lba8505","title":"Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Lung cancer; Pharmacokinetics; Osimertinib; Urology; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058255,0.001112358,0.001440887,0.0004658195,0.0002306006,0.0008973526,0.000691711,0.0009693081,0.004632505],"category_scores_gemma":[0.0008597006,0.000411633,0.00132473,0.0003554037,0.0006767929,0.001016171,0.000340605,0.002875015,0.0006901727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007200883,"about_ca_system_score_gemma":0.0008478497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006440415,"about_ca_topic_score_gemma":0.002369297,"domain_scores_codex":[0.9996722,0.0001396924,0.0000268655,0.00005642015,0.00002930569,0.00007565137],"domain_scores_gemma":[0.9995079,0.0001125608,0.0001219922,0.0000281654,0.0000209903,0.0002084262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.939875,0.008606277,0.0009351558,0.0005210377,0.000955321,0.00004497526,0.00005621296,0.0006723119,0.01037527,0.0001463252,0.001174635,0.03663748],"study_design_scores_gemma":[0.6788371,0.3078526,0.005898055,0.00006473839,0.001256049,0.0001162632,0.00004429087,0.001274229,0.002853732,0.0003054462,0.001471656,0.00002593207],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990828,0.003694774,0.0003915027,0.0004645225,0.0003343288,0.001064735,0.0007564704,0.0001498027,0.002315823],"genre_scores_gemma":[0.9941015,0.001355098,0.0005543166,0.0004267608,0.0002301202,0.0008331224,0.0007808612,0.00001860373,0.00169957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004632505,"threshold_uncertainty_score":0.01549727,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03199664137692556,"score_gpt":0.4276833612972435,"score_spread":0.395686719920318,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}